• Type of startup : Life Sciences
  • Date of entry : 07/07/2022
  • Associated laboratory(ies) : INSERM UMR 1091 UCA

VTX is developing a non-cytotoxic, differentiating anti-tumour therapeutic strategy that neutralises the cancer stem cells responsible for tumour initiation, progression and resistance to treatment.

Back